Rubius Therapeutics, Inc. - RUBY STOCK NEWS

Rubius Therapeutics (Nasdaq: RUBY) announced that Dr. Pablo J. Cagnoni will participate in a fireside chat at the Guggenheim Nantucket Therapeutics Conference on September 29, 2022, at 11:15 AM EDT. The event will be available through a live audio webcast on their website, with a replay accessible for 90 days after. Rubius specializes in Red Cell Therapeutics™ for treating cancer and autoimmune diseases. The company was recognized as a top workplace in Massachusetts and Rhode Island, highlighting its positive work environment.

Rubius Therapeutics (Nasdaq: RUBY) announced a corporate restructuring to focus on advancing its next generation red blood cell-based cell conjugation platform. The company has decided to discontinue its ongoing Phase 1 clinical trials for RTX-240 and RTX-224 due to recent technical progress in an alternative format for making Red Cell Therapeutics. Cost-saving measures include a 75% reduction in workforce, extending the cash runway to the end of 2023. The restructuring aims to enhance the efficacy and reduce the cost of generating their products while maintaining tolerability.

Rubius Therapeutics has scheduled an investor teleconference and webcast on September 13, 2022, at 7:30 a.m. EDT to provide a strategic update on its cellular medicines development. The company is focused on creating Red Cell Therapeutics to treat cancer and autoimmune diseases using its proprietary RED PLATFORM®. An audio webcast will be available live and archived for 90 days. Rubius Therapeutics has been recognized among the Top Places to Work in Massachusetts and Best Places to Work in Rhode Island.

Rubius Therapeutics (Nasdaq: RUBY) reported its Q2 2022 financial results, revealing a net loss of $44.2 million, or $0.49 per share, compared to a loss of $50.2 million, or $0.56 per share in Q2 2021. The company continues its clinical trials with RTX-240 in combination with pembrolizumab for advanced solid tumors, with initial results expected in 2H 2022. Additionally, notable preclinical findings were presented regarding the prevention of type 1 diabetes. Rubius holds $140.7 million in cash as of June 30, 2022, down from $225.8 million at year-end 2021.

Rubius Therapeutics (Nasdaq: RUBY) announced plans to report its second quarter financial results on August 9, 2022, before the market opens. The company is focused on developing Red Cell Therapeutics™, innovative treatments for cancer and autoimmune diseases using its proprietary RED PLATFORM® technology. Notably, the company will not host a teleconference alongside the financial results announcement. Rubius has received accolades, being recognized as a top workplace in Massachusetts and Rhode Island.

HotSpot Therapeutics announces the appointment of Jose 'Pepe' Carmona to its Board of Directors, highlighting his 20 years of experience in the biopharmaceutical sector. Currently the CFO of Rubius Therapeutics (RUBY), Carmona has previously held leadership roles in Radius Health and Innocoll Holdings. His financial expertise is expected to support HotSpot's growth as it aims to transition into a clinical-stage company focused on allosteric drug development for cancer and autoimmune diseases.

Rubius Therapeutics (Nasdaq: RUBY) has appointed Susanne Schaffert, Ph.D., to its board of directors. Schaffert brings over 25 years of pharmaceutical experience, most recently as President of Novartis Oncology, and will support the advancement of Rubius' oncology pipeline, including RTX-240 and RTX-224. She succeeds Anne Prener, M.D., Ph.D., who has stepped down from the board. Dr. Schaffert's expertise is expected to drive progress in Red Cell Therapeutics™ aimed at treating cancer and autoimmune diseases.

Rubius Therapeutics (Nasdaq: RUBY) announced promising preclinical data at the FOCIS 2022 Annual Meeting, demonstrating that their Red Cell Therapeutics™ might prevent Type 1 Diabetes in the non-obese diabetes (NOD) model. The study showed effective tolerance induction and bystander suppression, with 0 out of 5 mice developing the disease after treatment. This breakthrough suggests potential applications for other autoimmune diseases like celiac disease and multiple sclerosis. A clinical candidate for the Type 1 Diabetes program is expected to be selected later this year.

Rubius Therapeutics, a clinical-stage biopharmaceutical firm, has announced that Pablo J. Cagnoni, M.D., the CEO, will engage in a fireside chat during the Jefferies Global Healthcare Conference on June 9, 2022, at 2:30 p.m. EDT. The event will be accessible via a live audio webcast on the company’s website, with an archived replay available for 90 days post-event. Rubius is focused on developing Red Cell Therapeutics™ for treating cancer and autoimmune diseases through its proprietary RED PLATFORM® technology.